BRAF and neoplasm: In an extensive follow-up examination involving adults who had not received prior treatment for metastatic melanoma and whose tumor tissue tested positive for V600 mutations, it was noted that BRAF inhibition with vemurafenib led to an improvement of survival rates [8,12,13,14].